Skip to content
Screener

Stoke Therapeutics, Inc. STOK Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.34M-8.3%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.09M+44.0%
CalAmp logo
CalAmpCAMP
$384K-87.5%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$1.27M+10.4%
Septerna, Inc. logo
Septerna, Inc.SEPN
$2.41M+18.9%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$3.3M+2.6%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.11B+189%
Enterprise value$1.96B+210%
P/S65.8×+62.1×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemAs of March 31, 2026As of December 31, 2025
Accrued employee compensation costs3,076$13,975
Accrued professional costs3,222965
Accrued research and development costs13,67022,028
Current portion of operating lease liabilities2,4333,007
Other current liabilities1,5001,060
$23,901$41,035

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s operating lease liabilities (current)?
Stoke Therapeutics, Inc. (STOK) reported operating lease liabilities (current) of $2.43M in Q1 2026.
How has Stoke Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?
Stoke Therapeutics, Inc.'s operating lease liabilities (current) increased by 3.5% year-over-year, from $2.35M to $2.43M.
What is the long-term trend for Stoke Therapeutics, Inc.'s operating lease liabilities (current)?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 23.0% compound annual growth rate (CAGR), from $1.07M to $3.01M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Stoke Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude